2022
Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis.
Neilan AM, Landovitz RJ, Le MH, Grinsztejn B, Freedberg KA, McCauley M, Wattananimitgul N, Cohen MS, Ciaranello AL, Clement ME, Reddy KP, Hyle EP, Paltiel AD, Walensky RP. Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis. Annals Of Internal Medicine 2022, 175: 479-489. PMID: 35099992, PMCID: PMC9087297, DOI: 10.7326/m21-1548.Peer-Reviewed Original ResearchConceptsCAB-LAHIV preexposure prophylaxisCost-effectiveness analysisPreexposure prophylaxisHigh riskNational InstituteIncremental cost-effectiveness ratioCost-effectiveness ratioBase-case analysisHealth care systemEunice KennedyInjectable cabotegravirPrEP retentionOral PrEPHIV PrEPHIV incidenceBlood InstituteDisoproxil fumarateNational HeartChild healthSide effectsTransgender womenInfectious diseasesPrEPQALY
2021
The Value of Total Knee Replacement in Patients With Knee Osteoarthritis and a Body Mass Index of 40 kg/m2 or Greater : A Cost-Effectiveness Analysis.
Chen AT, Bronsther CI, Stanley EE, Paltiel AD, Sullivan JK, Collins JE, Neogi T, Katz JN, Losina E. The Value of Total Knee Replacement in Patients With Knee Osteoarthritis and a Body Mass Index of 40 kg/m2 or Greater : A Cost-Effectiveness Analysis. Annals Of Internal Medicine 2021, 174: 747-757. PMID: 33750190, PMCID: PMC8288249, DOI: 10.7326/m20-4722.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioBody mass indexTotal knee replacementKnee replacementCost-effectiveness analysisTKR recipientsKnee osteoarthritisMass indexEnd-stage knee osteoarthritisLong-term clinical benefitCost-effective strategyPreoperative pain levelNational InstituteOsteoarthritis Policy ModelLifetime medical costsCost-effectiveness ratioBase-case analysisProbabilistic sensitivity analysesMultiple comorbiditiesCost-effectiveness perspectivePain levelsComplication rateClinical benefitCardiovascular diseaseMedical costsClinical and Economic Effects of Widespread Rapid Testing to Decrease SARS-CoV-2 Transmission.
Paltiel AD, Zheng A, Sax PE. Clinical and Economic Effects of Widespread Rapid Testing to Decrease SARS-CoV-2 Transmission. Annals Of Internal Medicine 2021, 174: 803-810. PMID: 33683930, PMCID: PMC9317280, DOI: 10.7326/m21-0510.Peer-Reviewed Original ResearchConceptsSARS-CoV-2Antigen testingHome testingSARS-CoV-2 antigen testingIncremental cost-effectiveness ratioSARS-CoV-2 transmissionCost-effectiveness ratioBase-case analysisRapid testingPrevention guidanceDeath avertedDisease progressionInpatient careCommunity transmissionOutcome estimatesTesting interventionsViral transmissionDisease controlInfectionNumber of personsCumulative infectionsNational containment strategyWarrants considerationU.S. populationDeath
2020
Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis.
Walensky RP, Horn T, McCann NC, Freedberg KA, Paltiel AD. Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis. Annals Of Internal Medicine 2020, 172: 583-590. PMID: 32150602, PMCID: PMC7217721, DOI: 10.7326/m19-3478.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioCost-effectiveness analysisFair priceCost-effectiveness ratioBase-case analysisJustifiable priceSocietal willingnessComparative pricingHealth care sectorPricesTime horizonEnd-stage renal diseaseCases of ESRDQALYDemand PrEPCare sectorEconomic savingsHIV preexposure prophylaxisSensitivity analysisCostPreexposure prophylaxisLife effectsHorizonPricingDiscount
2017
Do Less Harm: Evaluating HIV Programmatic Alternatives in Response to Cutbacks in Foreign Aid.
Walensky RP, Borre ED, Bekker LG, Hyle EP, Gonsalves GS, Wood R, Eholié SP, Weinstein MC, Anglaret X, Freedberg KA, Paltiel AD. Do Less Harm: Evaluating HIV Programmatic Alternatives in Response to Cutbacks in Foreign Aid. Annals Of Internal Medicine 2017, 167: 618-629. PMID: 28847013, PMCID: PMC5675810, DOI: 10.7326/m17-1358.Peer-Reviewed Original ResearchConceptsYears of lifeHIV transmissionHIV programsFuture incident casesSecond-line ARTHIV care continuumViral load monitoringAdverse clinical consequencesResource-limited nationsBase-case analysisCurrent standardHIV deathsIncident casesCôte d'IvoireCare continuumART efficacyClinical consequencesHIV detectionLess HarmHIVSocietal perspectiveProductivity costsNational InstituteDeathYears
2016
The Anticipated Clinical and Economic Effects of 90-90-90 in South Africa.
Walensky RP, Borre ED, Bekker LG, Resch SC, Hyle EP, Wood R, Weinstein MC, Ciaranello AL, Freedberg KA, Paltiel AD. The Anticipated Clinical and Economic Effects of 90-90-90 in South Africa. Annals Of Internal Medicine 2016, 165: 325-33. PMID: 27240120, PMCID: PMC5012932, DOI: 10.7326/m16-0799.Peer-Reviewed Original ResearchConceptsOverall virologic suppressionVirologic suppressionHIV transmissionYears of lifeMaternal orphansTarget strategyHIV/AIDS 90HIV case detectionIncremental cost-effectiveness ratioJoint United Nations ProgrammeHIV transmission ratesSouth African HIVCost of careCost-effectiveness ratioBase-case analysisAIDS 90Incident infectionsAfrican HIVUnited Nations ProgrammeCase detectionHIV detectionTreatment targetsSouth African survey dataRapid treatmentSocietal perspective
2015
Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration
Losina E, Michl G, Collins JE, Hunter DJ, Jordan JM, Yelin E, Paltiel AD, Katz JN. Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration. Osteoarthritis And Cartilage 2015, 24: 776-785. PMID: 26746146, PMCID: PMC4838505, DOI: 10.1016/j.joca.2015.12.011.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAnti-Inflammatory Agents, Non-SteroidalCost-Benefit AnalysisDisease ProgressionDrug CostsFemaleHealth Care CostsHealth Services ResearchHumansInfusions, IntravenousInjections, SubcutaneousMaleMiddle AgedModels, EconometricNerve Growth FactorOsteoarthritis, KneePain MeasurementQuality-Adjusted Life YearsSelf AdministrationUnited StatesConceptsNerve growth factor inhibitorsQuality-adjusted life yearsStandard of careTotal knee replacement surgeryIncremental cost-effectiveness ratioGrowth factor inhibitorsKnee osteoarthritisFactor inhibitorsOA progressionSelf-administered subcutaneous injectionsSevere knee osteoarthritisDirect medical costsKnee replacement surgeryQuality-adjusted life expectancyOsteoarthritis Policy ModelCost-effectiveness ratioMeans of administrationBase-case analysisCost-effective treatmentHospital deliveryIntravenous infusionDisease progressionLifetime riskReplacement surgerySubcutaneous injection
2014
Cost-effectiveness of canine vaccination to prevent human rabies in rural Tanzania.
Fitzpatrick MC, Hampson K, Cleaveland S, Mzimbiri I, Lankester F, Lembo T, Meyers LA, Paltiel AD, Galvani AP. Cost-effectiveness of canine vaccination to prevent human rabies in rural Tanzania. Annals Of Internal Medicine 2014, 160: 91-100. PMID: 24592494, PMCID: PMC4084874, DOI: 10.7326/m13-0542.Peer-Reviewed Original ResearchConceptsVaccination campaignCanine vaccinationPrompt postexposure prophylaxisBase-case analysisVaccination coverageHuman rabiesSocietal willingnessProbability-based evaluationU.S. dollarsEconomic outcomesContact-tracing studiesEmpirical uncertaintyRural AfricaRural TanzaniaOptimal vaccination coverageOngoing vaccination campaignRabies vaccination campaignsGreat uncertaintyAnnual mortality ratePostexposure prophylaxisEpidemiologic variablesTransmission of rabiesHealth burdenWillingnessMortality rate
2009
When to start antiretroviral therapy in resource-limited settings.
Walensky RP, Wolf LL, Wood R, Fofana MO, Freedberg KA, Martinson NA, Paltiel AD, Anglaret X, Weinstein MC, Losina E. When to start antiretroviral therapy in resource-limited settings. Annals Of Internal Medicine 2009, 151: 157-66. PMID: 19620143, PMCID: PMC3092478, DOI: 10.7326/0003-4819-151-3-200908040-00138.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAnti-HIV AgentsAnti-Infective AgentsCD4 Lymphocyte CountCohort StudiesComputer SimulationCost-Benefit AnalysisDecision TreesDisease ProgressionDrug Administration ScheduleHealth Care CostsHIV InfectionsHumansLife ExpectancySensitivity and SpecificitySouth AfricaTrimethoprim, Sulfamethoxazole Drug CombinationConceptsAntiretroviral therapyCD4 countLong-term survivalCells/LART initiationCells/L.ART initiation strategiesIncremental cost-effectiveness ratioSevere opportunistic diseaseDoris Duke Charitable FoundationLife expectancyCD4 count thresholdHIV treatment decisionsCost-effectiveness ratioInternational clinical trialsBase-case analysisResource-limited settingsYears of lifeCost-effectiveness analysisPerson's life expectancyObservational cohortCD4 thresholdHIV diseaseTreatment guidelinesEarly therapy
2006
Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs.
Paltiel AD, Walensky RP, Schackman BR, Seage GR, Mercincavage LM, Weinstein MC, Freedberg KA. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Annals Of Internal Medicine 2006, 145: 797-806. PMID: 17146064, DOI: 10.7326/0003-4819-145-11-200612050-00004.Peer-Reviewed Original ResearchConceptsCost-effectiveness ratioDollars/QALYHIV prevalenceAnnual incidenceHIV infectionRoutine HIVAntiretroviral therapyIncremental cost-effectiveness ratioModerate HIV prevalenceUndetected HIV infectionVoluntary HIV screeningUndiagnosed HIV infectionRapid HIV testingHIV patient careHIV transmission riskOne-time screeningQuality-adjusted survivalLifetime medical costsServices Utilization SurveySecondary transmissionBase-case analysisCost-effectiveness analysisHIV screeningObservational cohortHIV testing